China Pharma Holdings

China Pharma Holdings, Inc. engages in the development, manufacture, and marketing of pharmaceutical products. The firm’s product portfolio includes Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases, Comprehensive Healthcare, and Protective Products. The company was founded by Zhi Lin Li on January 28, 1999 and is headquartered in Haikou, China.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HAIKOU, China , Aug. 19, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that through Hainan Helpson Medical and Biotechnology Co., Ltd. ("Helpson"), our wholly owned subsidiary, it expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 in China.

China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025

HAIKOU, China , Feb. 23, 2024 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-5 reverse stock split on its common stock effective Wednesday, March 6, 2024, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI".

China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split

HAIKOU, China , Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China. According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 344 million patients are suffering from DED worldwide, accounting for 30% of the total number of ophthalmic outpatient visits, with an annual increase of 10%.

China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device

HAIKOU, China , Aug. 9, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its wholly-owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd. (hereinafter referred to as "Helpson") has received the "Drug Supplementary Application Approval Notice" for its candesartan tablets by National Medical Products Administration of China (hereinafter referred to as NMPA"), indicating that the Company's candesartan tablets have passed the quality and efficacy consistency evaluation of generic drugs.

China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs

HAIKOU, China , Feb. 24, 2023 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Monday, March 6, 2023, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI".

China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

HAIKOU, China , Dec. 28, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the launch of N95 medical protective mask ("N95 mask").   On December 26, Hainan Medical Products Administration issued the Registration Certificate of N95 medical protective masks to Hainan Helpson Medical & Biotechnology Co., Ltd.

China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask

HAIKOU, China , Dec. 15, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its drugs were listed in The Catalogue of Medicines for People Infected with COVID-19 (First Edition) (hereinafter referred to as the Catalogue) published by People's Daily on December 12, 2022.   Recently, China has completely ended its strict quarantine and zero case policies in response to COVID-19 pandemic in the past three years.

China Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19

The stock price of China Pharma (CPHI) has been volatile this week. This is why.

China Pharma (CPHI) Stock: Why It Has Been Volatile This Week

HAIKOU, China , Dec. 5, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the Acquisition of Dry Eye Disease Therapeutic Device Project. This device has a patent Epidemiological research shows that the incidence rate of DED is about 25% to 30%, and the incidence rate of people over 65-year-old is 75% in China According to the Research Report on the Market Status of the Global Dry Eye Disease Drug Industry in 2022 (1), the market size of DED drugs in China in 2021 was approximately RMB3.85 billion (approximately US$0.55 billion), resulting a 12.4% year-on-year growth In the field of DED and visual fatigue, this product will fill in the market gap of medical therapeutic apparatus We have established sales channels in more than 30 provincial and municipal hospitals, as well as OTC markets in China for more than 20 years; which will strongly support the launch and promotion of this device Dry eye disease (DED) refers to the general term of a variety of diseases related to abnormal tear quality, quantity, or dynamics, accompanied by eye discomfort (dry eyes, tingling, burning, gritty feeling, etc.

China Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device Project

HAIKOU, China , Dec. 2, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on December 1, 2022, received a notification (the "Deficiency Letter") from the NYSE American LLC (the "NYSE American") stating that the Company was not in compliance with a certain NYSE American continued listing standard relating to stockholders' equity, or Section 1003(a)(ii) of the NYSE American Company Guide, which requires an issuer to have stockholders' equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in its four most recent fiscal years. The Deficiency Letter noted that Company had stockholders' equity of $2.8 million as of September 30, 2022, and has reported losses from continuing operations and/or net losses in its four most recent fiscal years ended December 31, 2021.

China Pharma Announces Receipt of Noncompliance Notice from NYSE American

HAIKOU, China , Oct. 1, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI; the "Company") today announced that on September 26, 2022, the Company received notification (the "Deficiency Letter") from the NYSE AMERICAN LLC ("NYSE American") informing it that the Company is not in compliance with certain NYSE American continued listing standards (the "Listing Standards"). The Deficiency Letter indicated that the Company's securities had been selling for a low price per share for a substantial period of time and, most recently, the average price of the Company's common stock had been below $0.20 on a 30-day average as of September 22, 2022.

China Pharma Announces Receipt of Notification of NYSE American Listing Deficiency

HAIKOU, China , July 18, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on July 15, 2022, the Company submitted a plan of compliance to NYSE American LLC ("NYSE American" or the "Exchange") to address the deficiency in the Company's stockholders' equity as pointed out in the letter from the Exchange dated June 15, 2022 (the "Letter"). As previously released in a press release dated June 22, 2022, according to the Letter, in order to maintain its listing, the Company must submit a plan of compliance by July 15, 2022 addressing how it intends to regain compliance with Section 1003(a)(iii) of the Company Guide by December 15, 2023.

China Pharma Announced the Submission of a Plan of Compliance to NYSE American

Qutoutiao Inc - ADR

Zynerba Pharmaceuticals

Check these three penny stocks out for your watchlist right now The post 3 Penny Stocks, Are They Worth Buying Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks, Are They Worth Buying Right Now?

HAIKOU, China, March 31, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the fiscal year ended December 31, 2021. Full Year Highlights Revenue was $9.6 million in fiscal year 2021, compared to $10.9 million in fiscal year 2020; Gross margin was 3.7% in fiscal year 2021, compared to 18.0% in fiscal year 2020; Loss from operations was $2.9 million in fiscal year 2021, compared to $2.6 million in fiscal year 2020; Net loss was $3.4 million in fiscal year 2021, compared to $2.9 million in fiscal year 2020.

China Pharma Holdings, Inc. Reports Fiscal Year 2021 Financial Results

HAIKOU, China, Nov. 12, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI)  ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the financial results for the quarter ended September 30, 2021. Revenue decreased by 17.6% to $2.0 million for the three months ended September 30, 2021, as compared to $2.4 million for the three months ended September 30, 2020.

China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results

Flora Growth Corp

Gold Resource

LiveXLive Media

LM Funding America

NeoPhotonics

Wish

Move over Reddit! These popular Discord stocks just might give fans of speculative opportunities the swing trades they're looking for.

7 Discord Stocks Investors Are Pumping Higher

HAIKOU, China, Aug. 13, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI)  ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the financial results for the quarter ended June 30, 2021. Revenue decreased by 35.9% to $2.4 million for the three months ended June 30, 2021, as compared to $3.8 million for the three months ended June 30, 2020.

China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results

HAIKOU, China , Aug. 5, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the results of the key benchmark tests of consistency evaluation to apply for the National Medical Products Administration's (NMPA) approval.

China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval

HAIKOU, China, June 9, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced plans to launch a highly purified NMN+PQQ product following the recent successful completion of a pilot scale test. β-Nicotinamide mononucleotide (NMN) is a derivative of the B-vitamin niacin, which is believed to significantly improve health and wellness.

China Pharma to Launch Highly Purified NMN+PQQ Product

HAIKOU, China, May 14, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2021. Revenue increased by 33.7% to $2.4 million for the three months ended March 31, 2021, as compared to $1.8 million for the three months ended March 31, 2020.

China Pharma Holdings, Inc. Reports 33% YoY Increase in First Quarter 2021 Revenue

HAIKOU, China, April 19, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, commented on the policy statements in "Several Special Measures to Support the Construction of Hainan Free Trade Port to Relax Market Access" released by the National Development and Reform Commission and the Ministry of Commerce in April.  This statement follows the release of the Overall Plan for the Construction of Hainan Free Trade Port in June 2020 and the establishment of the Hainan Boao Lecheng International Medical Tourism Pilot District in 2013, which were both approved by the State Council.

China Pharma Expects Considerable Increase in Growth Opportunities Related to Hainan Free Trade Port

Cyanotech

SeaChange International

Universe Pharmaceuticals

Shares of several penny stocks are on the rise today as Reddit investors continue to pick out the top ones to take a risk on. The post Top Penny Stocks Today: What to Know About BAYP, SEAC, UPC, CPHI, CYAN Stocks appeared first on InvestorPlace.

Top Penny Stocks Today: What to Know About BAYP, SEAC, UPC, CPHI, CYAN Stocks

The stock price of China Pharma Holdings, Inc. (NYSEAMERICAN: CPHI) has increased by over 200% pre-market. This is why it happened.

CPHI Stock Price Increases Over 200% Pre-Market: Why It Happened

HAIKOU CITY, China , March 26, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI)  ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the fiscal year ended December 31, 20 20 . Full Year Highlights Revenue was both $10.9 million in fiscal year 2020 and 2019 , respectively ; Gross margin was 1 8.0 % in fiscal year 20 20 , compared to 1 3.6 % in fiscal year 201 9; Loss from operations was $2 .6 million in fiscal year 20 20 compared to $ 2 0.4 million in fiscal year 201 9 , which represented a n improvement of $ 17.8 million; Net loss was $2 .9 million in fiscal year 20 20 compared to $ 20.7 million in fiscal year 201 9.

China Pharma Holdings, Inc. Reports Fiscal Year 2020 Financial Results

Face mask play China Pharma Holdings is trending higher today, and investors are noticing. Here is what you should know about CPHI stock.

News for China Pharma Holdings Stock (CPHI)